Publikation
TOF mass spectrometry-based immunopeptidomics refines tumor antigen identification.
Wissenschaftlicher Artikel/Review - 17.11.2023
Hoenisch Gravel Naomi, Nelde Annika, Bauer Jens, Mühlenbruch Lena, Schroeder Sarah M, Neidert Marian Christoph, Scheid Jonas, Lemke Steffen, Dubbelaar MariLisa, Wacker Marcel, Dengler Anna, Klein Reinhild, Mauz Paul-Stefan, Löwenheim Hubert, Hauri-Hohl Mathias, Martin Roland, Hennenlotter Jörg, Stenzl Arnulf, Heitmann Jonas S, Salih Helmut Rainer, Rammensee Hans-Georg, Walz Juliane Sarah
Bereiche
PubMed
DOI
Kontakt
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Seiten
Kurzbeschreibung/Zielsetzung
T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identification and characterization of naturally presented tumor-associated peptides, a key prerequisite for the development of T cell-based immunotherapies. This study reports on the implementation of ion mobility separation-based time-of-flight (TOF) MS for next-generation immunopeptidomics, enabling high-speed and sensitive detection of HLA-presented peptides. Applying TOF-based immunopeptidomics, a novel extensive benign dataset was generated from 94 primary benign samples of solid tissue and hematological origin, which enabled the expansion of benign reference immunopeptidome databases with > 150,000 HLA-presented peptides, the refinement of previously described tumor antigens, as well as the identification of frequently presented self antigens and not yet described tumor antigens comprising low abundant mutation-derived neoepitopes that might serve as targets for future cancer immunotherapy development.